FRESH-PEF3286-en
Therapeutic options for hepatitis B and C: a French nationwide cohort study
HEPATHER
| Name | Country code |
|---|---|
| France | fr |
['Clinical data','Participant-reported health data','Biological data','Socio-demographic data']
Individuals
| Topic | Vocabulary |
|---|---|
| Infectious disease medicine | health theme |
| Hepatology | health theme |
| Diseases of the blood or blood-forming organs | cim-11 |
| Healthcare system determinants: Use of care | health determinant |
| Healthcare system determinants | health determinant |
{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
}
],
"level_age_clusion_I": [
{
"value": "Young Adult (19 to 24 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D055815"
}
},
{
"value": "Adult (25 to 44 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000328"
}
},
{
"value": "Middle Aged (45 to 64 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008875"
}
},
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
},
{
"value": "Aged, 80 and over (80 years and more)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000369"
}
}
],
"level_type_clusion_I": "Patients population",
"level_type_clusion_other": "",
"clusion_I": "",
"clusion_E": ""
}
| Name |
|---|
| Stanislas;POL |
| Fabrice;CARRAT |
| Name |
|---|
| AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES |
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) |
| Name |
|---|
| AGENCE NATIONALE DE LA RECHERCHE (ANR) |
| AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES |
['Through organizations (health services or institutions, schools, businesses, etc.)']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Access on specific project only
Observational Study
| Start |
|---|
| 2012-01-01 |
Accessibility of the database will be determined case by case by the executive committee in agreement with the scientific committee. The intellectual property and contractual issues will be managed by Inserm Transfert. Special attention will be paid on confidentiality, ethical issues and on the use of the biobank to yield the greatest scientific value to the community and avoid depletion of this finite ressource. The proposal will be examined by the executive committee. The committee will assist academic and private researchers with queries and will advise on data quality, study design and data analysis if necessary. The committee will ensure the coherence with other projects. The executive committee will evaluate methodological aspects and scientific relevance based on reports from the scientific committee. Independent external experts will provide advice on decisions relative to access rights, for example on issues related to the access on one industrial to data linked to the product of another industrial. It will prioritize projects. In preparation for data sharing, much attention will be paid to the wording within subject consent documents. The flexibility of web-based database will also facilitate the addition of new questionnaires for ancillary studies.
The executive committee will establish policies to facilitate data sharing and to provide a mechanism for tracking publications related to and resulting from Hepather data. Moreover the executive committee will monitor contributions of the ancillary studies to the community and will require results to be incorporated into a resource database for use by other researchers.
{"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}
| Name | |
|---|---|
| Stanislas;POL | stanislas.pol@aphp.fr |
| Fabrice;CARRAT | fabrice.carrat@iplesp.upmc.fr |
FRESH-PEF3286-en